COMPOSITIONS COMPRISING OR CONSISTING OF POLYDATIN FOR USE IN TREATMENT OF BONE DISEAS
The patent concerns the possible use of polydatin for the treatment of pathologies characterized by reduced bone mass. Polydatin is an oligostilbene that can be extracted in abundant quantities from the roots of the Polygonum Cuspidatum plant and, according to our studies about osteoblastic proliferation and differentiation, is able to increase osteogenic activity.
Skeletal pathologies are widespread in the world population, more than 200 million people are osteoporosis patients and have a high probability of fracture. Polydatin is a substance of natural origin, free of the side effects related to the use of synthetic drugs, currently administered for the treatment of bone loss diseases . Our experiments carried out in two-dimensional cultures (2D) and in cells grown on Scaffold (3D), have shown that polydatin is able to increase the activity of osteoblasts (ALP) and the deposition of Bone Matrix. The compositions comprising or consisting of polydatin may be administered orally (for example capsules or tablets, solutions, emulsions) or topically (oils, creams, ointments), or even through an appropriate enrichment of the active ingredient in functional foods
- Patients with traumatic-degenerative pathologies of the skeleton and oral cavity;
- Osteoporosis patients;
- Molecule of natural origin;
- Antioxidant activity on the whole organism;
- Possibility of topical use;